ME: 23andMe Inc. Average Forecast Price

Symbol and logo of brand 23andMe Holding Co (ME)

23andMe Holding Co. (ME) is currently fighting for survival, losing valuable bioinformatics specialists due to mass layoffs. The business is suffering from declining interest in genetics and severe pricing pressure from competitors. The price action, recorded at 8.39, illustrates the position of a company that relies on a unique genomic dataset to collaborate with pharmaceutical behemoths in drug development.

ME 23andMe Inc.: Analyst Consensus Forecast in the range 07/04/2022 - 04/05/2025

Analytical breakdowns for 23andMe Inc. (ME)

- market price and analyst price targets:
Stock Quotes 23andme.com|ME - Analyst Consensus Forecast
- market capitalization information:
Market Value 23andMe Inc.|ME - Total Company Value
- shareholders' equity book value data:
Accounting Value per Share 23andMe|ME - Book Capitalization|Market-to-Book Ratio 23andme.com|ME - Company Total Assets
- issuer credit burden and liquidity indicators:
Debt to Equity Ratio 23andMe Holding Co.|ME - Long-Term Debt to Capital|Short-Term Debt to Capital 23andMe Inc|ME - Company Debts|Debt to Book Value Ratio 23andMe Inc.|ME - Company Long-Term Debts|Company Short-Term Debts 23andMe|Quick Liquidity 23andme.com
- business earnings and investment ratios data:
ME - Net Income|Expected Net Profit 23andMe Holding Co.|ME - Price to Earnings Ratio|Market Cap to Projected Earnings 23andMe Holding Co|ME - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio 23andMe Inc.|ME - Profit before payment of interest, taxes and amortization|Net earnings per share for the last four quarters 23andMe|ME - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months 23andme.com|ME - Earnings growth in current year|Earnings growth forecast for next year 23andMe Holding Co.
Fundamental company analysis:23andme.com (ME)
Manufactured products of 23andMe Inc.

This indicator aggregates expert expectations regarding the asset's fair value, identifying deviations of the market price from the fundamentally justified average. By analyzing the market's average target price, an investor assesses the capitalization potential of 23andMe Holding Co. (ME), which is based on the value of unique genetic databases and the expertise of leading data scientists in the field of personalized medicine.

Competing companies

Consensus Target agilent.com A|Analyst Consensus Forecast DGX (Quest Diagnostics Incorporated)|Illumina Inc (ILMN) - Average Forecast Price|EXAS - Price Target Chart|Revvity Corp (RVTY) - Consensus Target|BIO: Analyst Consensus Forecast|Average Forecast Price anbio.com (NNNN)|SHC (Sotera Health) - Analyst Consensus Forecast|Broker Consensus Forecast QDEL (Quidel Corporation)|Analyst Consensus Forecast OPK|Analyst Consensus Forecast CareDx Inc (CDNA)|Price Target Chart Maravai LifeSciences MRVI|FLGT: Broker Consensus Forecast|Standard BioTools - Analyst Consensus Forecast|CTKB - Analyst Consensus Forecast|OraSure Technologies Inc (OSUR) - Price Target Chart|XGN (Exagen) - Price Target Chart|Consensus Target MDXH|Average Forecast Price luciddx.com LUCD|Price Target Chart Prenetics Global (PRE)|Analyst Median Target imdxinc.com|Analyst Consensus Forecast TRIB (Trinity Biotech)|Analyst Median Target ProPhase Labs Corp (PRPH)|AIMD - Price Target Chart|Analyst Median Target codiagnostics.com CODX|HeartSciences (HSCS) - Price Target Chart|Consensus Target Biomerica Inc.|CDIO (Cardio Diagnostics Holdings Inc.) - Analyst Consensus Forecast|Analyst Consensus Forecast Onconetix Corporation|Price Target Chart Virax Biolabs Group (VRAX)|bluejaydx.com - Broker Consensus Forecast|Analyst Consensus Forecast AWH (Aspira Women's Health Inc.)|AXDX: Broker Consensus Forecast|CNTG - Price Target Chart|Enzo Biochem, Inc. (ENZ) - Consensus Target|FRES: Analyst Consensus Forecast|Average Forecast Price Genetic Technologies Limited (GENE)|Consensus Target PMD